Evidence map›Paper›PMID 40135920›Full record

ArticleAntimicrobial agents and chemotherapy2025

Contribution of front-line, standard-of-care drugs to bactericidal responses, resistance emergence, and cure in murine models of easy- or hard-to-treat tuberculosis disease.

Nathan Peroutka-Bigus, Elizabeth J Brooks, Michelle E Ramey, Hope D'Erasmo, Jackie P Ernest, Allison A Bauman, Lisa K Woolhiser, Radojka M Savic, Anne J Lenaerts, Bree B Aldridge and 2 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Nathan Peroutka-BigusMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA.ORCID 0000-0001-5212-9541
Elizabeth J BrooksMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA.
Michelle E RameyMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA.
Hope D'ErasmoDepartment of Molecular Biology and Microbiology, Tufts University School of Medicine, Boston, Massachusetts, USA.
Jackie P ErnestDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA.
Allison A BaumanMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA.
Lisa K WoolhiserMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA.
Radojka M SavicDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA.ORCID 0000-0003-3143-5579
Anne J LenaertsMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA.
Bree B AldridgeDepartment of Molecular Biology and Microbiology, Tufts University School of Medicine, Boston, Massachusetts, USA.ORCID 0000-0003-2236-1424
Jansy P SarathyCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.ORCID 0000-0002-1532-146X
Gregory T RobertsonMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA.ORCID 0000-0001-7157-4034

Funding

Preclinical Design and Clinical Translation of TB Regimens (PReDicTR) ConsortiumUM1AI179699 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Kelly E. Dooley, ERIC L NUERMBERGER · 2024 to 2026
$22.2M
Bill and Melinda Gates Foundation OPP1033596Bill and Melinda Gates Foundation OPP1037174Gates Foundation INV-009105Gates Foundation INV-027276National Institute of Allergy and Infectious Diseases 1UM1AI179699-NIAID NIH HHS UM1 AI179699
6 · The paper itself

Abstract

By assessing the standard-of-care regimen for tuberculosis (TB) in BALB/c and C3HeB/FeJ mice, we demonstrate that rifampin, with or without pyrazinamide, is essential for an effective bactericidal response and suppression of resistance. Potency measurements in an

Indexed as

Antitubercular AgentsMycobacterium tuberculosisPyrazinamideRifampinTuberculosisAnimalsDisease Models, AnimalDrug Resistance, BacterialFemaleMiceMice, Inbred BALB CMice, Inbred C3HMicrobial Sensitivity TestsRabbitsAntitubercular AgentsPyrazinamideRifampinC3HeB/FeJcaseumrelapserifafourtuberculosis

Identifiers

PMID40135920
PMCPMC12057366

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.